Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

Osteoporosis International

Volumn 27, Issue 12, 2016, Pages 3409-3425

  Dede, A D ^a   Trovas, G ^a   Chronopoulos, E ^a   Triantafyllopoulos, I K ^a   Dontas, I ^a   Papaioannou, N ^a   Tournis, S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bisphosphonates; Denosumab; Fractures; Healing; Pain; Strontium ranelate; Teriparatide

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; STRONTIUM RANELATE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGE; BONE DENSITY; BONE FRAGILITY; BONE TURNOVER; CLINICAL FEATURE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THALASSEMIA; THALASSEMIA ASSOCIATED OSTEOPOROSIS; TREATMENT PLANNING; COMPLICATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; THALASSEMIA;

EID: 84981244756     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-016-3719-z     Document Type: Review

References (123)

1. Weatherall DJ (1997) The thalassaemias. BMJ 314(7095):1675–1678
2. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40–47
3. Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86(6):480–487
4. Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E (2007) Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 82(4):255–265
5. Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, Maragkos K, Kontogianni K, Lafioniatis S, Vrettou E, Koutsouka F, Papadakis A, Mihos A, Eftihiadis E, Farmaki K, Papageorgiou O, Tapaki G, Maili P, Theohari M, Drosou M, Kartasis Z, Aggelaki M, Basileiadi A, Adamopoulos I, Lafiatis I, Galanopoulos A, Xanthopoulidis G, Dimitriadou E, Mprimi A, Stamatopoulou M, Haile ED, Tsironi M, Anastasiadis A, Kalmanti M, Papadopoulou M, Panori E, Dimoxenou P, Tsirka A, Georgakopoulos D, Drandrakis P, Dionisopoulou D, Ntalamaga A, Davros I, Karagiorga M, Group GHS (2012) A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 91(9):1451–1458
6. Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B, Airaghi L, Zanaboni L, Cappellini MD (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207–1213
7. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ, Network TCR (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557
8. Exarchou E, Politou C, Vretou E, Pasparakis D, Madessis G, Caramerou A (1984) Fractures and epiphyseal deformities in beta-thalassemia. Clin Orthop Relat Res 189:229–233
9. Finsterbush A, Farber I, Mogle P, Goldfarb A (1985) Fracture patterns in thalassemia. Clin Orthop Relat Res 192:132–136
10. Dines DM, Canale VC, Arnold WD (1976) Fractures in thalassemia. J Bone Joint Surg Am 58(5):662–666
11. Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Robertson S, Neumayr L, Vichinsky EP, Multi-Center Iron Overload Study Group (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43(1):162–168
12. Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38(4):571–575
13. Ruggiero L, De Sanctis V (1998) Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. J Pediatr Endocrinol Metab 11(Suppl 3):773–778
14. Sutipornpalangkul W, Janechetsadatham Y, Siritanaratkul N, Harnroongroj T (2010) Prevalence of fractures among Thais with thalassaemia syndromes. Singap Med J 51(10):817–821
15. Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N, Chuncharunee S (2013) Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 35(3):212–217
16. Bielinski BK, Darbyshire PJ, Mathers L, Crabtree NJ, Kirk JM, Stirling HF, Shaw NJ (2003) Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 120(2):353–358
17. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC, Paul E, Bowden DK, Strauss BJ, Milat F (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J Bone Miner Res 29(11):2468–2473
18. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112(1):36–41
19. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Konstandelou E, Tolis G (2007) Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol 24(7):481–491
20. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19(5):722–727
21. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88(8):3966–3972
22. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R (2003) Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 18(9):1682–1688
23. Bordat C, Constans A, Bouet O, Blanc I, Trubert CL, Girot R, Cournot G (1993) Iron distribution in thalassemic bone by energy-loss spectroscopy and electron spectroscopic imaging. Calcif Tissue Int 53(1):29–37
24. Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, Pringle J, Porter JB (2012) Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 159(4):462–471
25. Rioja L, Girot R, Garabédian M, Cournot-Witmer G (1990) Bone disease in children with homozygous beta-thalassemia. Bone Miner 8(1):69–86
26. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909–913
27. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94(5):725–758
28. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2012) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int 23(3):1171–1176. doi:10.1007/s00198-010-1525-6
29. Memon AR, Butler JS, O’Riordan MV, Guerin E, Dimitrov BD, Harty JA (2013) Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment. J Clin Densitom 16(1):118–124. doi:10.1016/j.jocd.2012.07.003
30. van Lierop AH, Moester MJ, Hamdy NA, Papapoulos SE (2014) Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab 99(2):E252–E256
31. Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B, Annibali M, Emiliani R, Iliescu A, Rapa S, Rossi R, Ma L, Angelucci E, Schrier SL (2000) The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 96(10):3624–3629
32. Cazzola M, De Stefano P, Ponchio L, et al. (1995) Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 89(3):473–478
33. Arnett TR (2010) Acidosis, hypoxia and bone. Arch Biochem Biophys 503(1):103–109
34. Lu H, Lian L, Shi D, Zhao H, Dai Y (2015) Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells. Mol Med Rep 11(1):143–150
35. Shen GS, Yang Q, Jian JL, Zhao GY, Liu LL, Wang X, Zhang W, Huang X, Xu YJ (2014) Hepcidin1 knockout mice display defects in bone microarchitecture and changes of bone formation markers. Calcif Tissue Int 94(6):632–639
36. Hiram-Bab S, Liron T, Deshet-Unger N, et al. (2015) Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J 29(5):1890–1900
37. Yang Q, Jian J, Abramson SB, Huang X (2011) Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 26(6):1188–1196
38. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR (2004) Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 104(1):34–39
39. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103(4):911–915
40. Waung JA, Bassett JH, Williams GR (2012) Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab 23(4):155–162
41. Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tolis G (2006) Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 24(2):138–145
42. Dede AD, Tournis S, Dontas I, Trovas G (2014) Type 2 diabetes mellitus and fracture risk. Metabolism 63(12):1480–1490
43. Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D’Angelo E, Mirra N, Carnelli V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F (2008) Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol 69(2):202–207
44. Sadeghi-Bojd S, Hashemi M, Karimi M (2008) Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singap Med J 49(5):410–412
45. Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 24(6):239–244
46. Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ, Thalassemia Clinical Research Network (2011) Renal dysfunction in patients with thalassaemia. Br J Haematol 153(1):111–117
47. Baldan A, Giusti A, Bosi C, Malaventura C, Musso M, Forni GL, Volpato S, Zuliani G, Borgna-Pignatti C (2015) Klotho, a new marker for osteoporosis and muscle strength in β-thalassemia major. Blood Cells Mol Dis 55(4):396–401
48. Baldini M, Ulivieri FM, Forti S, Serafino S, Seghezzi S, Marcon A, Giarda F, Messina C, Cassinerio E, Aubry-Rozier B, Hans D, Cappellini MD (2014) Spine bone texture assessed by trabecular bone score (TBS) to evaluate bone health in thalassemia major. Calcif Tissue Int 95(6):540–546
49. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Strauss BJ, Bowden D, Milat F (2013) Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 24(7):1965–1971
50. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32(7):492–497
51. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ (1992) Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 14(1):48–56
52. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. (2014) Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd edition. Thalassaemia International Federation; ISBN-13: 978-9963-717-06-4
53. Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T (2013) A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol 30(8):748–754
54. Wong P, Polkinghorne K, Kerr PG, Doery JC, Gillespie MT, Larmour I, Fuller PJ, Bowden DK, Milat F (2016) Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone 85:55–58
55. Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, Amendola G, Pugliese U, Tartaglione I, Della Rocca F, Cinque P, Nobili B, Perrotta S (2014) Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. Am J Hematol 89(12):1102–1106
56. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G (2006) Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 38(6):888–892
57. Fung EB, Aguilar C, Micaily I, Haines D, Lal A (2011) Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol 86(10):871–873
58. Fung EB (2010) Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci 1202:188–196
59. Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N, Vichinsky EP, Giardina PJ, Thalassemia Clinical Research Network (2010) Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr 157(4):641–647
60. Trachtenberg F, Foote D, Martin M, Carson S, Coates T, Beams O, Vega O, Merelles-Pulcini M, Giardina PJ, Kleinert DA, Kwiatkowski J, Thompson AA, Neufeld EJ, Schilling L, Thayalasuthan V, Pakbaz Z, Yamashita R, Thalassemia Clinical Research Network (2010) Pain as an emergent issue in thalassemia. Am J Hematol 85(5):367–370
61. Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T, Eile J, Schilling L, Dinu B, Mendoza T, Gerstenberger E, Trachtenberg F, Vichinsky E, Thalassemia Clinical Research Network (2013) Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160(5):680–687
62. Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S, Green S, Calamaras D, Hess P, Yamashita R, Vichinsky E, Thalassemia Clinical Research Network (2013) Pain over time and its effects on life in thalassemia. Am J Hematol 88(11):939–943
63. Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D’Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E (2012) Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158(2):274–282
64. Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609
65. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91(9):1193–1202
66. Green ST, Martin MB, Haines D, Carson S, Coates T, Oliveros O, Gerstenberger E, Trachtenberg F, Kwiatkowski JL, Network TCR (2014) Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol 166(5):797–800
67. Angelopoulos NG, Katounda E, Rombopoulos G, Goula A, Kaltzidou V, Kaltsas D, Ioannis P, Tolis G (2006) Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy X-ray absorptiometry and quantitative computed tomography: a comparison study. J Pediatr Hematol Oncol 28(2):73–78
68. Mylona M, Leotsinides M, Alexandrides T, Zoumbos N, Dimopoulos PA (2005) Comparison of DXA, QCT and trabecular structure in beta-thalassaemia. Eur J Haematol 74(5):430–437
69. Bansal D, Venkateshwaran S, Khandelwal N, Marwaha RK (2011) Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study. Pediatr Blood Cancer 56(3):409–412
70. Argentiero A, Neglia C, Peluso A, di Rosa S, Ferrarese A, Di Tanna G, Caiaffa V, Benvenuto M, Cozma A, Chitano G, Agnello N, Paladini D, Baldi N, Distante A, Piscitelli P (2013) The ability of lumbar spine DXA and phalanx QUS to detect previous fractures in young thalassemic patients with hypogonadism, hypothyroidism, diabetes, and hepatitis-B: a 2-year subgroup analysis from the Taranto Area of Apulia Region. J Pediatr Hematol Oncol 35(6):e260–e264
71. Christoforidis A, Perifanis V, Papadopoulou E, Dimitriadou M, Kazantzidou E, Vlachaki E, Tsatra I (2009) Poor correlations between measurements of bone quality by quantitative ultrasound sonography and dual energy X-ray absorptiometry in patients with beta-thalassaemia major. Eur J Haematol 82(1):15–21
72. Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS (2011) Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 48(6):1305–1312
73. de Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, Sobti P, Skordis N, Karimi M, Raiola G, Galati MC, Bedair E, Fiscina B, El Kholy M, I-CET (International Network on Growth Disorders and Endocrine Complications in Thalassemia) (2013) Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 11(2):167–180
74. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ 342:d2040
75. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588):657–666
76. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O’Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, Women’s Health Initiative Investigators (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683
77. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 155(12):827–838
78. Avenell A, Gillespie WJ, Gillespie LD, O’Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 15(2):CD000227
79. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 26(1):35–41
80. Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB, Taylor EN (2014) Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int 25(8):2047–2056
81. Fung EB, Kwiatkowski JL, Huang JN, Gildengorin G, King JC, Vichinsky EP (2013) Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 98(4):960–971
82. Wu KH, Tsai FJ, Peng CT (2003) Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 82(10):637–640
83. Arcasoy A, Ocal G, Kemahli S, Berberoğlu M, Yildirmak Y, Canatan D, Akçurin S, Akar N, Uysal Z, Adiyaman P, Cetinkaya E (1999) Recombinant human growth hormone treatment in children with thalassemia major. Pediatr Int 41(6):655–661
84. Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G (2000) Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Investig 23(6):356–361
85. Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R, Hardin DS (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3(5):331–338
86. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, Crawford BA (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79(3):138–144
87. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30
88. Leung TF, Chu Y, Lee V, Cheng FW, Leung WK, Shing MM, Li CK (2009) Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin 33(5):361–369
89. Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S (2008) Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev Suppl 1:144–148
90. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123(4):730–737
91. Patıroğlu T, Torun YA, Kula M, Karakükçü M (2008) Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: two-year follow up. Turk J Hematol 25(2):79–82
92. Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21(6):402–408
93. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13(8):644–649
94. Shirani F, Iashkari M, Ahmadi AS, Arabi M, Asefi N (2012) Evaluation of alendronate efficacy on bone mineral density in thalassemic patients. Int J Hematol Oncol Stem Cell Res 6(4):20–24
95. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12(7):570–575
96. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P (1995) The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 42(3):279–287
97. Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO, Aziz Bedair EM, AbdelGawad M (2014) Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab 18(4):546–551. doi:10.4103/2230-8210.137516
98. Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R (2014) Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate. J Bone Miner Res 29(3):618–628
99. Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G, Tsiantouli E, Bellone F, Agostino RM, Piraino B, La Rosa MA, Salpietro C, Lasco A. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab. 2015 24. Epub
100. Blake GM, Lewiecki EM, Kendler DL, Fogelman I (2007) A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10(2):113–119
101. Canatan D, Akar N, Arcasoy A (1995) Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 93(1):20–24
102. Tournis S, Dede AD, Savvidis C, Triantafyllopoulos IK, Kattamis A, Papaioannou N (2015) Effects of teriparatide retreatment in a patient with β-thalassemia major. Transfusion 55(12):2905–2910
103. Trotta A, Corrado A, Cantatore FP (2010) Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review. Reumatismo 62(2):119–126
104. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, Stevenson JC (1994) Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 4(6):341–348
105. Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A (2011) Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 26(10):2430–2438
106. L’hermite M, Simoncini T, Fuller S, Genazzani AR (2008) Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 60(3–4):185–201
107. Cappellini MD, Poggiali E, Taher AT, Musallam KM (2012) Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 5(5):505–511
108. Recommendation to restrict the use of Protelos/Osseor (Strontium ranelate), EMA/258269/2013. Accessed at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/04/news_detail_001774.jsp&mid=WC0b01ac058001d126
109. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504
110. Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM, IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23(12):2735–2748
111. Lewiecki EM (2011) Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 71(6):791–814
112. Lampropoulou-Adamidou K, Tournis S, Triantafyllopoulos IK (2016) Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. J Musculoskelet Neuronal Interact 16(1):75–78
113. Giusti A, Barone A, Balocco M, Pinto V, Pilotto A, Forni GL. (2015) Atypical fractures of the femur and bisphosphonate therapy in patients with beta thalassemia-associated osteoporosis: report of three cases [abstract #19]. In 10th Cooley’s Anemia Symposium, New York Academy of Sciences, New York
114. Leung F, Lau TW, To M, Luk KD, Kung AW. (2009) Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009. pii: bcr10.2008.1073.
115. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590
116. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243–254
117. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256
118. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24(4):726–736
119. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147–1155
120. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N, International Society of Clinical Densitometry (2013) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 17(2):275–280
121. Eghbali-Fatourechi G (2014) Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord 13(1):109
122. Pietri M, Lucarini S (2007) The orthopaedic treatment of fragility fractures. Clinical Cases in Mineral and Bone Metabolism 4(2):108–116
123. Michelson J, Cohen A (1988) Incidence and treatment of fractures in thalassemia. J Orthop Trauma 2(1):29–32